What is ABECMA? ABECMA (idecabtagene vicleucel) is a prescription medicine for the treatment of multiple myeloma in patients who have received at least three kinds of treatment regimens that have not worked or have stopped working. ABECMA is a medicine made from your own white blood cells; the cells are genetically modified to recognize and attack your multiple myeloma cells.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

Answers to frequently asked
questions about ABECMA®

Expand all

Collapse all

What is ABECMA?

ABECMA is a CAR T cell therapy made just for you. ABECMA cells are created by adding new hooks, called chimeric antigen receptors (CARs), to your existing T cells to fight multiple myeloma. This makes them
better able to attach to cancer cells and destroy them. ABECMA can also target normal, healthy cells. Learn more about how ABECMA works.

Is ABECMA right for me?

ABECMA may be a treatment option for you when multiple myeloma has come back (relapsed) or stopped responding to treatment (refractory) after you have received at least 2 kinds of treatment regimens, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. See if you've taken one of each of these drug classes.

How long does treatment with ABECMA take?

The treatment process for ABECMA happens in steps and not all at once.

  • Blood collection (apheresis): 2-6 hours
  • CAR T cell creation: About 4 weeks (times may vary)
  • Pre-infusion treatment: 3 days of short-course chemotherapy
  • One-time ABECMA infusion*: Up to 30 minutes per infusion bag (1 or more)
  • Monitoring: At least 4 weeks; 7 days at the treatment center and weeks 2-4 within 2 hours of the
    treatment center
  • Long-term monitoring: Regular check-ins with your healthcare team are still needed

Learn more about each step of the treatment process.

*The treatment process includes blood collection, CAR T cell creation, administration, and adverse event monitoring.

Why do I need to have a caregiver to receive ABECMA?

Caregivers play an essential role during your ABECMA treatment. During the first 7 days after receiving ABECMA, your healthcare team will monitor you for side effects. For the following 2-4 weeks, you will need to stay within 2 hours of the treatment center, and your caregiver will continue to monitor you. Learn more about your caregiver’s role.

Is ABECMA really a one-time treatment?

Multiple myeloma is currently an incurable disease, and everyone’s journey with it is different. ABECMA
is received as a one-time infusion,* and no repeated infusions, maintenance therapy, or daily pills are needed while responding to treatment. Regular check-ins with your healthcare team are still needed. Learn more about the treatment process of ABECMA.

*The treatment process includes blood collection, CAR T cell creation, administration, and adverse event monitoring.

Is remission possible with ABECMA?

While everyone responds differently to ABECMA, people treated with a one-time infusion* of ABECMA in a clinical study had 13.8 months (median) living without the multiple myeloma growing or spreading (called progression-free survival) vs 4.4 months (median) for those on standard treatment. Median is the middle number in a group of numbers arranged from lowest to highest. Learn more about the treatment outcomes and how people responded to ABECMA.

*The treatment process includes blood collection, CAR T cell creation, administration, and adverse event monitoring.

People who were given standard treatment got one of the following medication combinations: daratumumab, pomalidomide, dexamethasone (DPd); daratumumab, bortezomib, dexamethasone (DVd); ixazomib, lenalidomide, dexamethasone (IRd); carfilzomib, dexamethasone (Kd); or elotuzumab, pomalidomide, dexamethasone (EPd).

What are other people saying about ABECMA?

Other people who have been treated with ABECMA are sharing their personal stories. Each person’s journey is different, and your experience and results may vary. Hear personal stories about treatment

Are there resources to help me during my treatment journey?

ABECMA has many helpful resources. You can view or download the ABECMA Eligibility Guide,
Patient Brochure, Questions to Ask Your Doctor, and/or Medication Guide. There are also videos that
help explain the roles of your care team and provide an overview of the ABECMA treatment process.
See all ABECMA resources.

What kind of patient support is there for ABECMA?

Cell Therapy 360® is your partner throughout the CAR T cell therapy journey. It offers assistance programs
for you and your caregiver once a certified treatment center confirms that ABECMA is right for you.
Certain restrictions and eligibility requirements apply. Learn more about Cell Therapy 360.

For more education and support about multiple myeloma, consider reaching out to advocacy groups
and caregiver organizations. Find links to helpful groups and organizations.

How can I share my ABECMA story?

If you are interested in sharing your multiple myeloma diagnosis and ABECMA treatment story with others, please visit www.SharetoInspire.com or call us at 1-855-436-5866.

You can also hear from Mary and Jim, 2 people who have shared their ABECMA stories.

Learn what ABECMA is
and how it works

see how ABECMA works

Learn more about ABECMA